Sino-Life Group released its unaudited results for the six months ended 30 June 2026 (“1H 2026”), highlighting revenue pressure across its core funeral services operations in mainland China and Hong Kong alongside continued investment in new-energy and biotech projects.
Revenue and Profitability • Group revenue fell 26.50% year on year to RMB 26.47 million, driven mainly by a 25.60% drop in mainland funeral, cremation and cemetery income to RMB 25.52 million. • Gross profit declined 23.35% to RMB 10.13 million, although the gross margin inched up 1.6 percentage points to 38.3% on tighter cost control. • Loss attributable to owners widened to RMB 11.08 million from RMB 4.80 million a year earlier; basic and diluted loss per share increased to RMB 11.72 cents (1H 2025: RMB 5.08 cents). • Finance costs contracted 31.76% to RMB 0.51 million, reflecting lower interest on lease liabilities and bank loans.
Segment & Geographic Mix • Mainland China remained the dominant market, contributing 96.4% of group turnover. Taiwan and Hong Kong generated 2.6% and 1.0% respectively, while the Vietnam business was fully discontinued in 2025. • Biotechnical and other businesses recorded initial revenue of RMB 29,000 following the soft launch of new-energy unmanned ground-effect vehicles and related products.
Balance-sheet Highlights • Cash and bank balances stood at RMB 90.52 million (31 December 2025: RMB 98.43 million). • Net assets declined to RMB 85.76 million (31 December 2025: RMB 98.20 million) after recognising the period loss. • Gearing ratio (total liabilities/total assets) rose to 58.7% (31 December 2025: 57.2%). • Convertible bonds with carrying amount of RMB 11.89 million remained outstanding; no conversions or redemptions occurred in the period. • Bank borrowings decreased to RMB 0.53 million (31 December 2025: RMB 1.14 million).
Cash Flow and Investments • Operating cash outflow was RMB 2.91 million; net cash decreased by RMB 7.90 million to RMB 90.52 million. • Financial assets at fair value through profit or loss rose to RMB 36.98 million, including RMB 8.08 million in listed equities/ETFs and RMB 27.38 million in Taiwan-based mutual funds/unit trusts. • Capital commitments outstanding totalled RMB 2.69 million, mainly for equity investments.
Dividend & Share Capital • The Board did not recommend an interim dividend. • No share options were granted, exercised or lapsed; 1.85 million options remain outstanding, exercisable at HK$1.37 each until May 2032. • The company undertook no share repurchases during the period.
Management Commentary & Outlook Management cited subdued domestic demand, global trade tensions and high interest rates as key headwinds. The group aims to balance cash-generating funeral operations in Taiwan with growth investments in China’s low-altitude economy and biotechnology sectors. Cost discipline, streamlined operations and targeted R&D deployment remain priorities for the second half of 2026.